Compare Lupin Ltd with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs DISHMAN PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN DISHMAN PHARMA LUPIN/
DISHMAN PHARMA
 
P/E (TTM) x -95.9 25.1 - View Chart
P/BV x 2.9 3.3 85.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 LUPIN   DISHMAN PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
DISHMAN PHARMA
Mar-16
LUPIN/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs986374 263.4%   
Low Rs720129 558.9%   
Sales per share (Unadj.) Rs369.5197.8 186.8%  
Earnings per share (Unadj.) Rs13.421.2 63.2%  
Cash flow per share (Unadj.) Rs37.434.7 107.7%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs303.7179.9 168.8%  
Shares outstanding (eoy) m452.4980.69 560.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.31.3 181.5%   
Avg P/E ratio x63.611.9 536.4%  
P/CF ratio (eoy) x22.87.2 314.9%  
Price / Book Value ratio x2.81.4 200.8%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m386,06420,306 1,901.3%   
No. of employees `00017.70.8 2,133.2%   
Total wages/salary Rs m31,5135,355 588.5%   
Avg. sales/employee Rs Th9,453.819,252.7 49.1%   
Avg. wages/employee Rs Th1,782.06,459.5 27.6%   
Avg. net profit/employee Rs Th343.02,064.1 16.6%   
INCOME DATA
Net Sales Rs m167,18215,961 1,047.5%  
Other income Rs m3,640265 1,371.6%   
Total revenues Rs m170,82216,226 1,052.8%   
Gross profit Rs m28,8224,103 702.4%  
Depreciation Rs m10,8501,091 994.9%   
Interest Rs m3,078944 326.0%   
Profit before tax Rs m18,5342,334 794.2%   
Minority Interest Rs m-890-   
Prior Period Items Rs m381 3,409.1%   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,017624 1,445.9%   
Profit after tax Rs m6,0661,711 354.5%  
Gross profit margin %17.225.7 67.1%  
Effective tax rate %48.726.7 182.1%   
Net profit margin %3.610.7 33.8%  
BALANCE SHEET DATA
Current assets Rs m138,53611,018 1,257.4%   
Current liabilities Rs m61,2999,517 644.1%   
Net working cap to sales %46.29.4 491.3%  
Current ratio x2.31.2 195.2%  
Inventory Days Days84110 75.8%  
Debtors Days Days11235 322.7%  
Net fixed assets Rs m127,51616,304 782.1%   
Share capital Rs m905161 560.7%   
"Free" reserves Rs m136,51712,907 1,057.7%   
Net worth Rs m137,42214,516 946.7%   
Long term debt Rs m66,4174,189 1,585.4%   
Total assets Rs m279,49429,805 937.7%  
Interest coverage x7.03.5 202.3%   
Debt to equity ratio x0.50.3 167.5%  
Sales to assets ratio x0.60.5 111.7%   
Return on assets %3.38.9 36.7%  
Return on equity %4.411.8 37.4%  
Return on capital %8.917.5 50.8%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m59,4144,952 1,199.9%   
Fx outflow Rs m22,282697 3,197.8%   
Net fx Rs m37,1324,255 872.7%   
CASH FLOW
From Operations Rs m16,6602,786 597.9%  
From Investments Rs m-32,825-1,529 2,146.9%  
From Financial Activity Rs m7,441-941 -790.7%  
Net Cashflow Rs m-8,724316 -2,757.2%  

Share Holding

Indian Promoters % 46.6 61.4 75.9%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 3.7 305.4%  
FIIs % 31.9 12.7 251.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 22.1 45.7%  
Shareholders   98,259 46,261 212.4%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare LUPIN With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 224 Points Higher; Realty and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended on a positive note.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

More Views on News

Most Popular

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

Get Rich as the
Market Rebounds from Covid-19

Coronavirus Rebound
Get this special guide, authored by Equitymaster's top analysts, now.
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 29, 2020 03:35 PM

TRACK LUPIN

LUPIN - PANACEA BIOTECH COMPARISON

COMPARE LUPIN WITH

MARKET STATS